Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions not accepted — page 5

The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

Submissions

147 documents · page 5 of 5

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-THIRD-PARTY-/003Draft standard CEI-MS-15: Protocol for independent third-party…Dr Beatrijs HazelriggThe document set should be published in translation
DRAFT-APPEARANCE-S/011Draft standard CEI-MS-09: Assessment of appearance, cake integrity…Dr Anselm Ashworth-DanquahThe document should state what a reader ought to do
DRAFT-APPEARANCE-S/002Draft standard CEI-MS-09: Assessment of appearance, cake integrity…Dr Thaddeus Isaksen-Balogun industryThe document should not describe uses outside the approved indication
DRAFT-POORLY-RETAI/002Draft standard CEI-MS-19: Purity determination for peptides not…Dr Jerome PetrossianThe document set should be published in translation
DRAFT-POORLY-RETAI/014Draft standard CEI-MS-19: Purity determination for peptides not…Dr Nadezhda LavrentievThe standard should state a pass limit
DRAFT-POORLY-RETAI/003Draft standard CEI-MS-19: Purity determination for peptides not…Dr Valentin Castellanos-ReidThe standard should require documented operator competence
DRAFT-PHOTOSTABILI/002Draft standard CEI-MS-20: Photostability assessment of…Yusuf Whitmarsh-Obi industryThe document should not describe uses outside the approved indication
DRAFT-DUAL-VS-SING/006Draft synthesis: Dual and triple incretin receptor agonists compared…Dr Marisol Dunmore-EkpoThe document should state what a reader ought to do
DRAFT-DUAL-VS-SING/007Draft synthesis: Dual and triple incretin receptor agonists compared…Dr Frideswide NordhagenThe review question is drawn too broadly to be answerable
DRAFT-INCRETIN-CAR/011Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…Dr Liesbeth Zaleski-MbekiThe document should state what a reader ought to do
DRAFT-GASTROINTEST/008Draft synthesis: Gastrointestinal adverse events with incretin…Dr Oisín Marchetti-Bassey industryThe document should not describe uses outside the approved indication
DRAFT-GASTROINTEST/012Draft synthesis: Gastrointestinal adverse events with incretin…Dr Eamon ImmelmannThe document set should be published in translation
DRAFT-ORAL-VS-INJE/008Draft synthesis: Oral compared with injectable presentations of…Dr Zebedee Zaleski-MbekiThe review question is drawn too broadly to be answerable
DRAFT-SLEEP-APNOEA/006Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Lorcan Uttridge industryThe document should not describe uses outside the approved indication
DRAFT-COUNTERION-C/013Draft synthesis: Counter-ion content and its effect on delivered…Dr Lorcan Zaleski-MbekiThe document set should be published in translation
DRAFT-RUSSIAN-REGI/010Draft synthesis: Nationally registered neuropeptides and the…Sigrún VercingetorixThe document should state what a reader ought to do
DRAFT-SPONSOR-COND/008Draft synthesis: The consequences of a wholly sponsor-generated…Dr Ursina Ellsworth-VanceThe document should state what a reader ought to do
DRAFT-SPONSOR-COND/009Draft synthesis: The consequences of a wholly sponsor-generated…Dr Gaspard Wintringham industryThe document should not describe uses outside the approved indication
DRAFT-SURROGATE-OU/006Draft synthesis: Percentage weight change as a surrogate outcomeDr Mordecai Bellingham-OjoThe document should state what a reader ought to do
DRAFT-AMYLIN-ANALO/007Draft synthesis: Amylin analogues as monotherapy and in combinationDr Kolawole Isaksen-BalogunThe document should state what a reader ought to do
DRAFT-DISCONTINUED/001Draft synthesis: Discontinued development programmes as evidenceDr Quintus RautavaaraThe review question is drawn too broadly to be answerable
DRAFT-RECONSTITUTI/008Draft synthesis: Reconstitution practice and delivered doseDr Lorcan Uttridge industryThe document should not describe uses outside the approved indication
DRAFT-PANCREATITIS/008Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Hamish Nyquist-ObioraThe review question is drawn too broadly to be answerable
DRAFT-PANCREATITIS/007Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Marisol Dunmore-Ekpo industryThe document should not describe uses outside the approved indication
DRAFT-PANCREATITIS/010Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Wilhelmina ErlingssonThe document set should be published in translation
DRAFT-TIRZEPATIDE-/006Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Quintus KettlewellThe review question is drawn too broadly to be answerable
DRAFT-MITOCHONDRIA/011Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Vittoria YlönenThe document set should be published in translation

page 5 of 5

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.